X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DNTH103 is a potent monoclonal antibody engineered to selectively inhibitis only the active form of the C1s protein. It is being evaluated for the treatment of Multifocal Motor Neuropathy.
Lead Product(s): DNTH103
Therapeutic Area: Neurology Product Name: DNTH103
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein. It is being evaluated for the treatment of generalized myasthenia gravis.
Lead Product(s): DNTH103
Therapeutic Area: Immunology Product Name: DNTH103
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
The net proceeds will be used for the clinical development of DNTH103. It is a selective inhibitor of the active C1s protein for the treatment of neuromuscular & autoimmune disorders.
Lead Product(s): DNTH103
Therapeutic Area: Immunology Product Name: DNTH103
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 22, 2024
Details:
The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103, an investigational long-acting classical complement pathway inhibitor, currently in a Phase 1 trial to treat people with severe autoimmune diseases.
Lead Product(s): DNTH103
Therapeutic Area: Immunology Product Name: DNTH103
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Magenta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 03, 2023
Details:
The net financing will be used to fund DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications.
Lead Product(s): DNTH103
Therapeutic Area: Immunology Product Name: DNTH103
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fidelity Management & Research
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 03, 2023
Details:
DNTH103 is a next-generation monoclonal antibody that selectively targets only the active form of the C1s protein in the classical complement pathway. DNTH103 is designed as an infrequent and convenient subcutaneous injection.
Lead Product(s): DNTH103
Therapeutic Area: Immunology Product Name: DNTH103
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
